Shares of Evelo Biosciences Inc (NASDAQ:EVLO) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $22.75.
Several research firms have recently issued reports on EVLO. Chardan Capital began coverage on shares of Evelo Biosciences in a research report on Tuesday, January 29th. They set a “neutral” rating and a $10.00 price objective on the stock. ValuEngine cut shares of Evelo Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, December 21st.
A number of institutional investors and hedge funds have recently made changes to their positions in EVLO. Legal & General Group Plc increased its position in Evelo Biosciences by 169.8% in the fourth quarter. Legal & General Group Plc now owns 2,142 shares of the company’s stock worth $28,000 after purchasing an additional 1,348 shares during the last quarter. Bank of Montreal Can increased its position in Evelo Biosciences by 247.9% in the fourth quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock worth $37,000 after purchasing an additional 2,003 shares during the last quarter. Citigroup Inc. increased its position in Evelo Biosciences by 164.8% in the fourth quarter. Citigroup Inc. now owns 3,900 shares of the company’s stock worth $51,000 after purchasing an additional 2,427 shares during the last quarter. Larson Financial Group LLC increased its position in Evelo Biosciences by 29.5% in the first quarter. Larson Financial Group LLC now owns 7,268 shares of the company’s stock worth $58,000 after purchasing an additional 1,655 shares during the last quarter. Finally, American International Group Inc. increased its position in Evelo Biosciences by 155.2% in the fourth quarter. American International Group Inc. now owns 9,077 shares of the company’s stock worth $118,000 after purchasing an additional 5,520 shares during the last quarter. Institutional investors own 85.05% of the company’s stock.
Evelo Biosciences stock opened at $8.15 on Friday. The company has a market cap of $264.68 million and a PE ratio of -2.93. The company has a current ratio of 16.43, a quick ratio of 16.43 and a debt-to-equity ratio of 0.09. Evelo Biosciences has a 1 year low of $6.51 and a 1 year high of $16.75.
Evelo Biosciences (NASDAQ:EVLO) last released its quarterly earnings data on Thursday, February 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.09. As a group, analysts anticipate that Evelo Biosciences will post -2.48 earnings per share for the current fiscal year.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Recommended Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.